| 前收市價 | 33.42 |
| 開市 | 33.42 |
| 買盤 | 0.00 x 1200 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 31.84 - 33.70 |
| 52 週波幅 | 12.40 - 44.19 |
| 成交量 | |
| 平均成交量 | 2,176,903 |
| 市值 | 4.852B |
| Beta 值 (5 年，每月) | 0.71 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.96 |
| 業績公佈日 | 2024年2月01日 - 2024年2月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 49.08 |
Insider Monkey15 Best-Performing Stocks in the Last 12 Months
In this article, we will take a look at the 15 best-performing stocks in the last 12 months. To see more such companies, go directly to 5 Best-Performing Stocks in the Last 12 Months. The US stock market has been performing unusually well in 2023. The most recent catalyst came after the Federal Reserve’s fight […]
InvestorPlaceThe Quant Trading System Picking Stocks That Soar 300%
Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St
BenzingaImmunovant Could Potentially Be An M&A Target, Writes Analyst
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30. The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn). Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies. Related:
